The active ingredient in Replagal is agalsidase alfa. Replagal is produced in a human cell line, and has exactly the same amino acid structure as the naturally occurring α-galactosidase A.1
Enzyme replacement therapy with Replagal is designed to directly replace the α-galactosidase A enzyme that is missing or deficient in patients with Fabry disease. This reduces the Gb3 that accumulates in cells, and helps correct the pathophysiology of Fabry disease.1
Click on the video to find out more about how enzyme replacement therapy with Replagal works in patients with Fabry disease.